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Conclusions: The HPV infection in Germany was lower than 
expected. Also in our investigation it appears that HPV positive 
patients have a better clinical outcome than HPV negative 
patients. 
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SINONASAL UNDIFFERENTIATED CARCINOMA WITH BRAIN 
METASTASIS: A CASE REPORT AND REVIEW OF LITERATURE 
Julianna Sienna, Nhu-Tram Agnes Nguyen, Ian David Hodson, 
Brandon Meyers 
McMaster University, Hamilton, ON 
 
Introduction: Sinonasal undifferentiated carcinoma (SNUC) is a 
rare aggressive neoplasm arising in the nasal cavity and paranasal 
sinuses. Although intracranial extension from SNUC is common in 
patients with locally advance disease, distant central nervous 
system metastasis from SNUC is an extremely rare occurrence.  
Methods and Materials:  Herein, we present a case, and review 
the limited literature on overall management and outcomes of 
patients with SNUC and management and outcomes of patients 
with SNUC with brain metastases. 
Results:  We report a case of an 80 year old man who presented 
with a locally advanced SNUC involving ethmoid, sphenoid and 
maxillary sinuses and bilateral lymph nodes from level I-V, 
cT4N2cM0. Given his age and the initial extent of his primary 
tumour, he was treated with neo-adjuvant chemotherapy 
followed by palliative chemoradiation with a split course of 50 
Gy in 40 fractions delivered twice a day. Four months after his 
treatments, he developed a recurrence at the left lower eyelid 
and left frontal sinus, intra-abdominal metastases and a left 
cerebellar metastasis. A single fraction of 22 Gy was delivered to 
the cerebellar lesion using stereotactic radiosurgery.  
Upon review of the literature, we found only two cases reported 
of brain metastases that were not due to local intracranial 
extension from the original mass, in which detailed treatment 
information was reported. One patient with partially controlled 
local disease had a left temporoparietal lesion treated with a 
combination of bone marrow transplant and CAV chemotherapy 
and had a partial response. This patient died of disease at 8 
months. The second case was treated initially with surgical 
resection and post-operative chemotherapy and radiation and 
lived for at least another two years while developing further 
metastases- at the time of the printed manuscript the patient 
was still alive.  
Conclusions:  We advocate that aggressive treatment of 
advanced SNUC may be pursued in selected patients. We suggest 
a registry for rare head and neck cancers such as SNUC to help 
guide treatment. 
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STEREOTACTIC BODY RADIATION THERAPY WITH 48GY IN 3 
FRACTIONS IS A SAFE AND EFFECTIVE TREATMENT FOR EARLY 
STAGE NSCLC PATIENTS  
Khaled Adil, Andre Boustead, Issam El Naqa, Jan Seuntjens, 
Marie Duclos, Neil Kopek, Sergio Faria, Bassam Abdulkarim, Hani 
Al-Halabi 
McGill University, Montreal, QC 
 
Purpose: Stereotactic body radiation therapy (SBRT) has become 
the standard therapy for inoperable early stage non-small cell 
lung cancer (NSCLC) and is increasingly more accepted as an 
alternative to surgery in operable patients. Despite the 
widespread use of SBRT in early stage NSCLC, the ideal dose 
fractionation for treating peripheral lesions is yet to be 
identified. Our institution has pioneered the use of 48 Gy in 3 
fractions as an SBRT dose fractionation schedule. We sought to 
evaluate the efficacy and toxicity associated with this regimen, 
in comparison to outcomes of patients treated at our institution 
with other commonly used SBRT dose regimens.  
Methods and Materials: We retrospectively reviewed the 
medical charts and radiation oncology records of consecutive 
patient with inoperable early stage NSCLC (T1-2 N0 M0) treated 
with SBRT at our institution between May 2010 and March 2015. 
Demographic patient data and dosimetric data regarding SBRT 
treatments were collected. Local/regional control, distant 
failure and overall survival were analyzed. Acute toxicity 
(defined as toxicity<90 days) and late toxicity (defined as 
toxicity>= 90 days) were also reported and graded as per 
standardized Common Terminology Criteria for Adverse Events 
(CTCAE) v4.0. 
Results: A total of 179 consecutive patients with a median age 
of 74.5 years were included. Ninety-eight patients with 110 
lesions received an SBRT dose of 48 Gy in 3 fractions over 5 - 7 
days (Group 1). Eighty one patients with 86 lesions (Group 2) 
received other standard SBRT fractionation schemes (25- 60 Gy 
in 1 – 5 fractions). After a median follow of 20 months (range 6 – 
95), 63% of patients treated with 48 Gy in 3 were alive. The crude 
rates of local, regional and distant failures in groups 1 and 2 were 
12.7%, 9.1%, 15.5% and 22.1%, 17.4% and 23.5%, respectively. 
The odds ratio for local failure, regional failure and distant 
metastasis were 0.5, 0.5 and 0.6 respectively in favour of the 48 
Gy in 3 dose fractionation. There were no cases of SBRT related 
Grade 3 or higher acute or late toxicity.  
Conclusions: The use of SBRT 48 Gy in 3 fractions for peripheral 
early stage NSCLC is associated with excellent outcomes and 
compare favourably with published results of 54 Gy in 3 fractions, 
and 48 Gy in 4 fractions. The favourable toxicity profile 
associated with using 48 Gy in 3 fractions highlights this regimen 
as safe and convenient option for the treatment of peripheral 
lesions in close proximity to the chest wall.  
 
235 
PROTON MAGNETIC RESONANCE SPECTROSCOPY (1H MRS) OF 
SPUTUM AND EXHALED BREATH CONDENSATE: A NON-INVASIVE 
TOOL FOR LUNG CANCER SCREENING  
Reem Alomran, Naseer Ahmed, Tedros Bezabeh, Renelle Myers, 
Omkar Ijare, Shantanu Banerji, Zoann Nugent, Zoheir Bshouty 
University of Manitoba, Winnipeg, MB 
 
Purpose: Lung cancer is the leading cause of cancer-specific 
mortality in North America. Main reason for the high mortality is 
the advanced stage at diagnosis in the majority of patients. Early 
detection of lung cancer by screening high-risk individuals has 
been proposed to improve survival. An effective screening 
program may prevent up to 80% of the deaths from lung cancer. 
We undertook this study to determine if 1H Magnetic Resonance 
Spectroscopy (MRS) of sputum and exhaled breath condensate 
samples can complement and or provide an alternate tool to 
screen and detect lung cancer among high-risk population. 
Methods and Materials: Sputum and Exhaled Breath Condensate 
(EBC) samples were collected from 15 patients. Pathologically 
confirmed non-small cell lung cancer (NSCLC, n = 8), and patients 
with respiratory conditions other than lung cancer (controls, n = 
7) were enrolled. Both sputum and EBC samples were collected 
in thirteen patients; two patients provided EBC samples only. 
Sputum samples were thawed and 250 mL of each sample was 
dispersed in 2M NaCl (prepared in PBS buffer) solution in the ratio 
1:1 (v/v) and vortexed to get homogenous clear suspension; 
frozen EBC samples were thawed and 500 mL neat sample was 
transferred into the NMR tube (with a reusable co-axial capillary 
tube containing standard TSP solution in D2O) for analysis. All 
MRS experiments were performed on a Bruker Avance 400 MHz 
NMR spectrometer at the University of Winnipeg. In order to 
detect metabolite signals, the water signals in both EBC and 
sputum samples were suppressed using PRESAT or excitation 
sculpting pulse sequence. The MRS lab staff was blind to the 
diagnosis until all the samples were analyzed. 
Results: In EBC samples, propionate was detected in 43% of the 
patients in both groups; with similar median concentration of the 
metabolite. Ethanol and acetate were detected in all patients, 
with relatively higher median concentration of the metabolites 
in the cancer group. Acetone and formate were detected in 75% 
and 50% of the cancer group and 43% and 57% of the control 
group, with higher median concentration of the metabolites in 
cancer group. Methanol was detected in 75% and 100% of the 
cancer and control group respectively, with median lower 
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concentration of the metabolite in the cancer group (p = 0.040). 
Subsequently, EBC samples were analyzed by an LC-QTOF-Mass 
Spectroscopy (MS) using a non-targeted approach. A total of 625 
compounds were detected in all EBC samples combined among 
which, four were up regulated in patients with lung cancer (T-
Test, p < 0.05). 
Conclusions: Lower concentrations of methanol (EBC), 
glycoprotein (sputum), absence of glucose in sputum identified 
through MRS and up regulation of four specific metabolites in EBC 
identified through MS in patients with known lung cancer suggest 
that MRS and MS may provide a lung cancer specific metabolic 
profile that can be used to develop a non-invasive tool to screen 
for lung cancer in high-risk population. 
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VALIDITY OF SPECIFIC GROWTH RATE IN STAGE I NON-SMALL CELL 
LUNG CANCER TREATED WITH STEREOTACTIC BODY 
RADIOTHERAPY (SBRT)  
Soha Atallah1, Graham Cook1, Robert MacRae1, Peter Cross1, 
Andrea Bezjak2, Andrew J Hope2, Jason Pantarotto1 
1The Ottawa Hospital, Radiation Oncology Division, Ottawa, ON 
2Princess Margaret Cancer Centre, Toronto, ON 
Purpose: Non-small cell lung cancer (NSCLC) frequently 
progresses during the interval between diagnosis and initiation 
of radiation therapy. We have previously demonstrated that 
tumour growth rate (GR) is an important predictor of local-
regional control and survival in early lung cancer patients treated 
with SBRT using specific growth rate (SGR) as a metric for tumour 
growth rate, and its median (0.43x10-2) as a cut off to group 
patients into high and low SGR groups. The aim of this study was 
to:  
1) validate SGR value of 0.43x10-2 as a metric for GR; and 2)
determine the influence of pre-treatment tumour SGR on 
outcomes of early stage NSCLC patients treated with SBRT at a 
second institution. 
Methods and Materials: A retrospective chart review of 160 
patients with pathologically confirmed T1-2 N0 NSCLC patients 
treated with SBRT between June 2010 and December 2012 was 
undertaken. Demographic and clinical data were collected from 
an institutional database. Time between diagnostic and 
simulation CT scans was calculated (t). Diagnostic CT was 
uploaded to Focal planning software v.4.70. Gross tumour was 
contoured on each slice using lung window to calculate Gross 
Tumour Volume (GTV1). The pre-treatment planning CT images 
were uploaded from archived files to record the pre-treatment 
GTV (GTV2). SGR was calculated using the equation: SGR = ln 
(GTV2/GTV1)/t). The SGR cut offv(0.43x10-2) from our previous 
data was used to group patients into two cohorts. Kaplan-Meier 
curves were constructed for both overall (OS) and failure-free 
survivals (FFS), and the log rank for comparison between high 
and low SGR groups. Multivariate analyses were performed using 
a Cox proportional hazard model with SGR and other relevant 
clinical factors. 
Results: Median time interval between initial diagnostic and 
planning CT scans was 87 days (range: 5-338). The median SGR 
was 0.418 x 10-2 (range -1.1x10-2; -5.1910-2). Median GTV1 was 
3.5 cm3 (range: 0.2; 51.9 cm3) and median GTV2 was 6 cm3 
(range: 0.2; 79.1 cm3). At median follow up period of 35.8 
months, the median OS was 54 months. Three years OS was 60%. 
Patients were grouped into high and low SGR using previously 
reported SGR median as a cut off (0.43x10-2). The median 
survival was 30.3 months for high SGR versus 44.6 months for low 
SGR (p = 0.02). The median FFS was 36 months for high SGR 
versus 51.9 months for low SGR groups respectively (p < 0.01). 
On univariable analysis, gender (p = < 0.01), Stage T2 (p < 0.01), 
and GTV2 (p < 0.01) were also predictive for OS and FFS. On 
multivariate analysis only male gender (p = 0.006) and GTV2 (p = 
0.04) were predictive for OS and high SGR (p = 0.01), male gender 
(p = < 0.01), and GTV2 (p = < 0.01) were independent predictors 
for poorer FFS. 
Conclusions: This analysis of an independent data set confirmed 
the validity of pre-treatment SGR. High SGR was associated with 
poorer outcome in patients with early stage NSCLC treated with 
SBRT. Further work to correlate and combine its use with 
biological markers is ongoing. 
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THE ROLE OF MID-TREATMENT 18F-FDG PET IN ASSESSING EARLY 
FUNCTIONAL RESPONSE AND PREDICTING OUTCOMES IN PATIENTS 
WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER 
UNDERGOING RADICAL CHEMORADIOTHERAPY  
Sarah Baker1, Ajb McEwan1, Terence Riauka1, Emmanuel 
Hudson1, Karen P Chu1, Hans-Sonke Jan1, Sunita Ghosh1, Rufus 
Scrimger1, Tirath Nijjar1, Don Yee2, Alysa Fairchild1, Zsolt 
Gabos1, Wilson Roa1 
1University of Alberta, Edmonton, AB 
2Cross Cancer Institute, Edmonton, AB 
Purpose: The prognostic and predictive value of 18F-FDG PET 
scans performed midway through curative-intent 
chemoradiotherapy for non-small cell lung cancer (NSCLC) 
remains to be established. This study aimed to determine if mid-
treatment 18F-FDG PET parameters predicted for the outcome 
of these patients. 
Methods and Materials: Between 2008 and 2012, nine 
consecutive patients with histologically-proven, unresected 
NSCLC who were fit to undergo curative-intent 
chemoradiotherapy (CRT) were prospectively accrued for study. 
18F-FDG PET scans were performed at baseline and after 20 
fractions of CRT. Mean standardized uptake value (SUVmean), 
maximum SUV (SUVmax) and metabolic tumour volume (MTV) 
were obtained. MTVs were automatically delineated at 50% of 
SUVmax for each lesion using a dedicated software package. 
Total lesion glycolysis (TLG) was calculated as mean SUV x MTV 
(cm3). Changes in TLG (Δ TLG) and SUVmax (Δ SUVmax) from 
baseline were used to quantify early metabolic tumour 
responses. Patients were followed for a median of 16 months 
(range 5.4 – 57.1 months). Repeat FDG-PET scan scans were 
performed at one, three, and 12 months following treatment or 
if patients had symptoms suggestive of locoregional progression 
or recurrence. Overall survival (OS) and progression-free survival 
(PFS) were calculated using the Kaplan-Meier method. Log-rank 
tests were used to compare the two survival curves. 
Results: Seven patients had AJCC Stage IIIa and two patients had 
Stage IIIb NSCLC. At the time of last follow up, three patients 
were alive and without recurrent disease. A reduction in TLG (Δ 
TLG) by 75% or more was associated with longer OS (12.5 versus 
16.4 months, p = 0.048). Baseline TLG values of 414.8 or less 
were associated with longer PFS (7.2 versus 9.0 months, p = 
0.048). Baseline and Δ SUVmax values were not associated with 
OS or PFS. 
Conclusions:  Early metabolic response midway through 
radiotherapy as quantified by Δ TLG by 75% or more was 
associated with longer OS. SUVmax at baseline and mid-
treatment and Δ SUVmax were not associated with OS or PFS. 
Early identification of poor CRT responders may allow for future 
clinical trials to improve outcomes in these patients, such as dose 
escalation with an additional RT boost. Larger studies are needed 
to confirm these findings 
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RISKS OF SABR FOR EARLY-STAGE NON-SMALL CELL LUNG CANCER 
WITH CO-EXISTING INTERSTITIAL LUNG DISEASE: A SYSTEMATIC 
REVIEW OF LITERATURE  
Hanbo Chen1, Alexander Louie1, R. Gabriel Boldt1, David Palma1, 
Esther Nossent2, Suresh Senan2 
1University of Western Ontario, London, ON  
2VU University Amsterdam, Amsterdam, The Netherlands 
Purpose: Stereotactic ablative radiotherapy (SABR) is an 
effective treatment for patients with peripherally-located early-
stage non-small cell lung cancer (ES-NSCLC). Treatment-related 
toxicity for SABR is uncommon, with a Grade 5 toxicity rate of 
0.4% in medically operable patients [Onishi et al. 2015]. Growing 
evidence suggests that patients with interstitial lung disease 
